Tenaya Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.3984 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 89.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Details
| Name | Tenaya Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 70 |
| Founded | 2016 |
| Ipo Date | 2021-07-30 |
| Ceo | Faraz Ali |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 15.00 |
| Isin | US87990A1060 |
| Cusip | 87990A106 |
| Cik | 1858848 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Faraz Ali M.B.A. | President, Chief Executive Officer and Director |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin M.D. | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding Ph.D. | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Eric Hyllengren | Chief Financial Officer and Principal Accounting Officer |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer |
Contact
| Address | 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080, United States |
| Phone | 650 825 6990 |
| Website | https://www.tenayatherapeutics.com |